Biosite, Beckman, Illumina, Caliper, EPA, Pfizer, OGT, ABI, Ciphergen | GenomeWeb
Biosite to Discuss Inverness Bid; Beckman Says Its Offer is Superior
 
Biosite this week said that it will start discussions with Inverness Medical Innovations about Inverness’ offer to buy the company for $90 a share.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.